Clinical data from the real world: efficacy of Crizotinib in Chinese patients with advanced ALK-rearranged non-small cell lung cancer and brain metastases

Brain metastasis in non small cell lung cancer (NSCLC) patients is often considered as a terminal stage of advanced disease. Crizotinib is a small-molecule tyrosine kinase inhibitor (TKI) for ALK-rearranged NSCLC patients. Herein, we conducted a retrospective study to explore how Crizotinib affects...

Descripción completa

Detalles Bibliográficos
Autores principales: Xing, Puyuan, Wang, Shouzheng, Hao, Xuezhi, Zhang, Tongtong, Li, Junling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356690/
https://www.ncbi.nlm.nih.gov/pubmed/27835868
http://dx.doi.org/10.18632/oncotarget.13179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356690/
https://www.ncbi.nlm.nih.gov/pubmed/27835868
http://dx.doi.org/10.18632/oncotarget.13179

Ejemplares similares